KYMR
Kymera Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.85 / 10
Outperform
Analyst consensus is overwhelmingly bullish—66.7% Strong Buy and 33.3% Buy from three analysts—with a 75% historical win rate for recent predictions. Money flow is equally encouraging: the fund flow score of 8.07/10 indicates exceptional inflow dynamics, with Extra-large and block flows positive despite negative Small, Medium, and Large flows. This confluence of bullish analyst views and robust fund inflows supports the technical strength, but investors should remain mindful of the still-fragile fundamentals.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
67%
Buy
33%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-28
InstitutionBarclays
Times predicted4
Historical Win Rate75.0%
What is the analyst consensus for KYMR?
- KYMR holds a Bullish analyst rating, with 67% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.85/10 (Outperform).
